These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 10903986

  • 1. Selective agonist of group II glutamate metabotropic receptors, LY354740, inhibits tolerance to analgesic effects of morphine in mice.
    Popik P, Kozela E, Pilc A.
    Br J Pharmacol; 2000 Jul; 130(6):1425-31. PubMed ID: 10903986
    [Abstract] [Full Text] [Related]

  • 2. Inhibitory effects of MPEP, an mGluR5 antagonist, and memantine, an N-methyl-D-aspartate receptor antagonist, on morphine antinociceptive tolerance in mice.
    Kozela E, Pilc A, Popik P.
    Psychopharmacology (Berl); 2003 Jan; 165(3):245-51. PubMed ID: 12442203
    [Abstract] [Full Text] [Related]

  • 3. The influence of AMN082, metabotropic glutamate receptor 7 (mGlu7) allosteric agonist on the acute and chronic antinociceptive effects of morphine in the tail-immersion test in mice: Comparison with mGlu5 and mGlu2/3 ligands.
    Gawel K, Jenda-Wojtanowska M, Gibula-Bruzda E, Kedzierska E, Filarowska J, Marszalek-Grabska M, Wojtanowski KK, Komsta L, Talarek S, Kotlinska JH.
    Physiol Behav; 2018 Mar 01; 185():112-120. PubMed ID: 29294304
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clinically available NMDA receptor antagonists memantine and dextromethorphan reverse existing tolerance to the antinociceptive effects of morphine in mice.
    Popik P, Kozela E, Danysz W.
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Apr 01; 361(4):425-32. PubMed ID: 10763858
    [Abstract] [Full Text] [Related]

  • 6. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.
    Monn JA, Valli MJ, Massey SM, Hansen MM, Kress TJ, Wepsiec JP, Harkness AR, Grutsch JL, Wright RA, Johnson BG, Andis SL, Kingston A, Tomlinson R, Lewis R, Griffey KR, Tizzano JP, Schoepp DD.
    J Med Chem; 1999 Mar 25; 42(6):1027-40. PubMed ID: 10090786
    [Abstract] [Full Text] [Related]

  • 7. Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice.
    Bilsky EJ, Inturrisi CE, Sadée W, Hruby VJ, Porreca F.
    Pain; 1996 Dec 25; 68(2-3):229-37. PubMed ID: 9121809
    [Abstract] [Full Text] [Related]

  • 8. The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats.
    Koltunowska D, Gibula-Bruzda E, Kotlinska JH.
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug 01; 45():242-9. PubMed ID: 23623810
    [Abstract] [Full Text] [Related]

  • 9. Potent, stereoselective, and brain region selective modulation of second messengers in the rat brain by (+)LY354740, a novel group II metabotropic glutamate receptor agonist.
    Schoepp DD, Johnson BG, Wright RA, Salhoff CR, Monn JA.
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Aug 01; 358(2):175-80. PubMed ID: 9750002
    [Abstract] [Full Text] [Related]

  • 10. mGluR5 antagonists that block calcium mobilization in vitro also reverse (S)-3,5-DHPG-induced hyperalgesia and morphine antinociceptive tolerance in vivo.
    Gabra BH, Smith FL, Navarro HA, Carroll FI, Dewey WL.
    Brain Res; 2008 Jan 02; 1187():58-66. PubMed ID: 18022146
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of NMDA receptor channel blockers, dizocilpine and memantine, on the development of opiate analgesic tolerance induced by repeated morphine exposures or social defeats in mice.
    Belozertseva IV, Bespalov AYu.
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Aug 02; 358(2):270-4. PubMed ID: 9750014
    [Abstract] [Full Text] [Related]

  • 14. LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors.
    Schoepp DD, Johnson BG, Wright RA, Salhoff CR, Mayne NG, Wu S, Cockerman SL, Burnett JP, Belegaje R, Bleakman D, Monn JA.
    Neuropharmacology; 1997 Jan 02; 36(1):1-11. PubMed ID: 9144636
    [Abstract] [Full Text] [Related]

  • 15. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
    Rorick-Kehn LM, Johnson BG, Burkey JL, Wright RA, Calligaro DO, Marek GJ, Nisenbaum ES, Catlow JT, Kingston AE, Giera DD, Herin MF, Monn JA, McKinzie DL, Schoepp DD.
    J Pharmacol Exp Ther; 2007 Apr 02; 321(1):308-17. PubMed ID: 17204749
    [Abstract] [Full Text] [Related]

  • 16. Effects of NMDA receptor antagonists on inhibition of morphine tolerance in rats: binding at mu-opioid receptors.
    Wong CS, Cherng CH, Luk HN, Ho ST, Tung CS.
    Eur J Pharmacol; 1996 Feb 15; 297(1-2):27-33. PubMed ID: 8851162
    [Abstract] [Full Text] [Related]

  • 17. LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats.
    Konieczny J, Ossowska K, Wolfarth S, Pilc A.
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Oct 15; 358(4):500-2. PubMed ID: 9826074
    [Abstract] [Full Text] [Related]

  • 18. Interaction of memantine and ketamine in morphine- and pentazocine-induced antinociception in mice.
    Malec D, Mandryk M, Fidecka S.
    Pharmacol Rep; 2008 Oct 15; 60(2):149-55. PubMed ID: 18443375
    [Abstract] [Full Text] [Related]

  • 19. Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists.
    Nakazato A, Kumagai T, Sakagami K, Yoshikawa R, Suzuki Y, Chaki S, Ito H, Taguchi T, Nakanishi S, Okuyama S.
    J Med Chem; 2000 Dec 14; 43(25):4893-909. PubMed ID: 11123999
    [Abstract] [Full Text] [Related]

  • 20. In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268).
    Fell MJ, Perry KW, Falcone JF, Johnson BG, Barth VN, Rash KS, Lucaites VL, Threlkeld PG, Monn JA, McKinzie DL, Marek GJ, Svensson KA, Nelson DL.
    J Pharmacol Exp Ther; 2009 Dec 14; 331(3):1126-36. PubMed ID: 19755662
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.